By Dale Mitchell and Jim Carter, LabConnect
As the focus for new drug development has transitioned from large blockbuster drugs to niche drugs for smaller patient populations, the biopharmaceutical landscape has changed dramatically. Companies now face the dual challenge of developing complex drugs for more targeted groups of patients combined with increasingly competitive timelines. Biomarkers serve as a valuable tool in achieving these goals, as they help researchers identify those patients who will most likely respond to a medication. Biomarkers also improve response rates, determine appropriate dosing, and minimize complications. Therefore, by adopting a method for seamlessly integrating and validating increasingly complex biomarker data, you can streamline your clinical trials, allowing life-saving drugs to reach the market – and patients – faster.